Mayo Clinic study underscores potential value of RABI-767

Mayo Clinic study underscores potential value of RABI-767

Lamassu Pharma announced the development of its lead therapeutic compound, RABI-767, may fulfill the unmet clinical need for the treatment of patients with pancreatitis, according to a press release.RABI-767 is a novel small molecule lipase inhibitor that is injected directly into the pancreas; in preclinical studies, it decreased the breakdown or release of unsaturated fats and saturated fats during acute pancreatitis attacks. The value of this therapeutic was underscored by recent Mayo Clinic research that found the rapid breakdown of unsaturated fat can worsen the course of severe acuteRead More

Share on facebook
Share on twitter
Share on linkedin